Prostate MRI combined with PSA-density may reduce the number of follow-up targeted biopsies in men on active surveillance for low-risk prostate cancer

By: Osses D.¹, Alberts A.¹, Verbeek J.², Drost F-J.¹, Roobol M.², Schoots I.³
¹Erasmus University Medical Center, Dept. of Urology, Dept. Radiology and Nuclear Medicine, Rotterdam, Netherlands, The, ²Erasmus University Medical Center, Dept. of Urology, Rotterdam, Netherlands, The, ³Erasmus University Medical Center, Dept. Radiology and Nuclear Medicine, Rotterdam, Netherlands, The

Prostate health index and multiparametric MRI to predict prostate cancer grade reclassification in active surveillance

By: Schwen Z.¹, Mamawala M.¹, Ross A.¹, Tosoian J.¹, Druskin S.¹, Sokoll L.², Epstein J.², Pavlovich C.¹, Carter H.B.¹
¹Johns Hopkins University School of Medicine, James Buchanan Brady Urological Institute and Dept. of Urology, Baltimore, United States of America, ²Johns Hopkins University School of Medicine, Dept. of Pathology, Baltimore, United States of America

Active surveillance: Off-protocol selection increases the risk of unfavorable outcomes

By: Soeterik T.¹, Van Melick H.¹, Dijksman L.¹, Biesma D.¹, Witjes F.², Van Basten J.P.³
¹St. Antonius Hospital, Dept. of Urology, Nieuwegein, Netherlands, The, ²Radboud University Nijmegen Medical Center, Dept. of Urology, Nijmegen, Netherlands, The, ³Canisius Wilhelmina Hospital, Dept. of Urology, Nijmegen, Netherlands, The

How can we expand active surveillance criteria in patients with low- and intermediate risk prostate cancer without increasing the risk of misclassification: Development of a novel risk calculator

By: Gandaglia G.¹, Van Den Bergh R.², Tilki D.³, Fossati N.¹, Ost P.⁴, Surcel C.⁵, Sooriakumaran P.⁶, Tsaur I.⁷, Valerio M.⁸, Kretschmer A.⁹, Montorsi F.¹, Graefen
538  
Risk inflation as a consequence of MRI-targeted biopsy of the prostate in men on active surveillance for low-risk prostate cancer?

By: Osses D. 1, Alberts A. 1, Verbeek J. 2, Drost F-J. 1, Roobol M. 2, Schoots I. 3
1Erasmus University Medical Center, Dept. of Urology, Dept. Radiology and Nuclear Medicine, Rotterdam, Netherlands, The, 2Erasmus University Medical Center, Dept. of Urology, Rotterdam, Netherlands, The, 3Erasmus University Medical Center, Dept. of Radiology and Nuclear Medicine, Rotterdam, Netherlands, The

539  
Is focal therapy for prostate cancer an attractive option? Results of an international survey from the young academic urologists (YAU) amongst 484 physicians

By: Marra G. 1, Ploussard G. 2, Ost P. 3, De Visschere P. 3, Sooriakumaran P. 4, Briganti A. 5, Gandaglia G. 5, Tilki D. 6, Surcel C. 7, Tsaur I. 8, Van Den Bergh R. 9, Kretschmer A. 10, Goonewardene S. 11, Borgmann H. 12, Gontero P. 1, Ahmed H. 13, Valerio M. 14
1Molinette Hospital - University of Studies of Turin, Dept. of Surgical Sciences, Turin, Italy, 2Saint Jean Languedoc Hospital, Dept. of Surgical Sciences, Toulouse, France, 3Ghent University, Dept. of Urology and Radiology, Ghent, Belgium, 4University College London Hospital, Dept. of Urology, London, United Kingdom, 5Vita e Salute University, San Raffaele Hospital, Dept. of Urology, Milan, Italy, 6Martini Klinik, Dept. of Urology, Hamburg, Germany, 7Fundeni Clinical Institute, Dept. of Urology, Bucharest, Romania, 8University of Mainz, Dept. of Urology, Mainz, Germany, 9University of Utrecht, Dept. of Urology, Utrecht, Netherlands, The, 10Ludwig-Maximilians-University of Munich, Dept. of Urology, Munich, Germany, 11Guy’s Hospital, Dept. of Urology, London, United Kingdom, 12University Hospital of Mainz, Dept. of Urology, Mainz, Germany, 13Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, 14Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland

540  
Active surveillance in prostate cancer patients: Predicting the chance of continuing AS after re-biopsy
To be confirmed

541  
Follow-up in active surveillance for prostate cancer: Variety in Dutch practice patterns
542    Prostate radiofrequency ablation focal treatment (proRAFT): Results of a prospective development study for localised prostate cancer

By:  Soeterik T. 1, Van Melick H. 2, Dijksman L. 1, Biesma D. 1, Witjes J. 3, Van Basten J-P. 4

1St. Antonius Hospital, Dept. of Value Based Healthcare, Nieuwegein, Netherlands, The, 2St. Antonius Hospital, Dept. of Urology, Nieuwegein, Netherlands, The, 3Radboud University Medical Centre, Dept. of Urology, Nijmegen, Netherlands, The, 4Canisius Wilhelmina Hospital, Dept. of Urology, Nijmegen, Netherlands, The

543    The clinical application and molecular mechanism of a blood based three gene signature underlying active surveillance of prostate cancer

To be confirmed

544    Cost-utility analysis of focal HIFU versus active surveillance for low- to intermediate-risk prostate cancer using a Markov multi-state Model

By:  Duroux T. 1, Robert G. 2, Rénard A. 3

1University College London, Division of Surgery and Interventional Sciences, London, United Kingdom, 2University College London, SITU, Division of Surgery and Interventional Sciences, London, United Kingdom, 3University College London Hospitals, Dept. of Radiology, London, United Kingdom, 4University College London Hospitals, Dept. of Pathology, London, United Kingdom, 5Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom

545    The importance of negative baseline multiparametric MRI to reduce the rate of early reclassification in low-risk prostate cancer patients managed with active surveillance

By:  Suardi N. 1, Mazzone E. 2, Gandaglia G. 2, Fossati N. 2, Gallina A. 2, Pini G. 1, Bravi C.A. 2, Gaboardi F. 1, Zaffuto E. 2, Bandini M. 2, Dell'Oglio P. 2, Stabile A. 2, Cardone G. 3, Mirone V. 4, Montironi R. 5, Shariat S. 6, Montorsi F. 2, Briganti A. 2

1San Raffaele Hospital Turro, Dept. of Urology, Milan, Italy, 2Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 3Vita-Salute University San Raffaele, Dept. of Radiology, Milan, Italy, 4Federico II University, Dept. of Urology, Naples, Italy, 5Politecnico University of Marche Region, Dept. of Pathology, Ancona, Italy, 6Medical University of Vienna, Dept. of Urology, Vienna, Austria

546    Consistent biopsy quality and Gleason grading within the global active surveillance GAP3 initiative: A prerequisite for future studies

By:  Van Der Kwast T. 1, Bruinsma S. 2, Nieboer D. 2, Helleman J. 2, Roobol M. 2
Focal HIFU: Higher recurrence rate in treatment of anterior compared to posterior lesions in prostate cancer


¹University Hospital Bern, Dept. of Urology, Bern, Switzerland, ²Dorset County Hospital NHS Trust, Dept. of Urology, Dorset, United Kingdom, ³UCLH NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁴University College London, Division of Surgery and International Sciences, London, United Kingdom, ⁵University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom, ⁶Hampshire Hospitals NHS Foundation Trust, Dept. of Urology, Basingstoke, United Kingdom, ⁷University of Zurich, Dept. of Political Science, Zurich, Switzerland, ⁸Springfield Hospital, Dept. of Urology, Chelmsford, United Kingdom, ⁹Royal County Surrey Hospital NHS Trust, Dept. of Urology, Surrey, United Kingdom, ¹⁰The Royal Marsden Hospital NHS Foundation Trust, Dept. of Academic Urology, London, United Kingdom, ¹¹Southmed Hospital, Dept. of Urology, Bristol, United Kingdom, ¹²University Hospital Insel, Dept. of Urology, Bern, Switzerland, ¹³The Princess Alexandra Hospital NHS Trust, Dept. of Urology, Harlow, United Kingdom, ¹⁴Charing Cross Hospital, Imperial Urology, London, United Kingdom